Antimalarial activities of new pyrrolo[3,2-f]quinazoline-1,3-diamine derivatives

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 12, 2005, Pages 4928-4933

  Guan, Jian ^a   Zhang, Quan ^a   O'Neil, Michael ^a   Obaldia III, Nicanor ^b   Ager, Arba ^c   Gerena, Lucia ^a   Lin, Ai J ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b Tropical Medicine Research/Gorgas Memorial Institute   (Panama)

^c UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; DIHYDROFOLATE REDUCTASE; MEFLOQUINE; PRIMAQUINE; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE; TAFENOQUINE; UNCLASSIFIED DRUG; WR 227825;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; CELL GROWTH; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; FEMALE; MALARIA; MALE; MONKEY; MOUSE; MUTATION; NONHUMAN; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM YOELII; PRIORITY JOURNAL; SPOROZOITE;

ANIMALS; ANTIMALARIALS; DISEASE MODELS, ANIMAL; MALARIA; MICE; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PYRROLES; QUINAZOLINES;

EID: 28844474431     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.12.4928-4933.2005     Document Type: Article

References (33)

1. Ager, A. L. 1984. Experimental models: rodent malaria models (in vivo), p. 225-254. In W. Peters and W. H. G. Richards (ed.), Handbook of experimental pharmacology: antimalarial drugs, vol. 68. Springer-Verlag, New York, N.Y.
2. Carson, P. E., C. I. Flanagan, C. E. Ickes, and A. S. Alving. 1956. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science (Washington, D.C.) 124:484-485.
3. Carson, P. E., R. Hohl, M. V. Nora, G. W. Parkhurst, T. Ahmad, S. Scanlan, and H. Frischer. 1981. Toxicology of the 8-aminoquinolines and generic factors associated with their toxicity in man. Bull. W. H. O. 59:427-437.
4. 3H]-hypoxanthine incorporation. Exp. Parasitol. 55:138-146.
5. Davidson, D. E., A. L. Ager, J. L. Brown, F. E. Chappie, R. E. Whitmire, and R. N. Rossan. 1981. Recent developments of tissue schizonticidal antimalarial drugs. Bull. W. H. O. 59:463-479.
6. Davoll, J., A. M. Johnson, H. J. Davies, O. D. Bird, J. Clarke, and E. F. Elslager. 1972. Folate antagonists. 2. 2,4-Diamino-6-([aralkyl and {heterocyclic}-methyl]amino)quinazolines, a novel class of antimetabolites of interest in drug-resistant malaria and Chagas' disease. J. Med. Chem. 15:812-826.
7. Desjardins, R. E., C. J. Canfield, J. D. Haynes, and J. D. Chulay. 1979. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob. Agents Chemother. 16:710-718.
8. Earle, W. C., and M. Perez. 1932. Enumeration of parasites in the blood of malarial patients. J. Lab. Clin. Med. 17:1124-1130.
9. Elslager, E. F., M. P. Hutt, P. Jacob, J. Johnson, B. Temporelli, L. M. Werbel, D. F. Worth, and L. Rane. 1979. Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)-quinazoline and related 2,4-diamino-6- [(phenyl and naphthyl)-sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity. J. Med. Chem. 22:1247-1257.
10. Elslager, E. F., J. Clarke, L. M. Werbel, D. F. Worth, and J. Davoll. 1972. Folate antagonists. 3. 2,4-Diamino-6-(heterocyclic)-quinazolines, a novel class of antimetabolites with potent antimalarial and antibacterial activity. J. Med. Chem. 15:827-836.
11. Genther, C. S., and C. C. Smith. 1977. Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli. J. Med. Chem. 20:237-243.
12. Greenberg, A. E., and H. O. Lobel. 1990. Mortality from Plasmodium falciparum malaria in travelers from the United States, 1959-1987. Ann. Intern. Med. 113:326-327.
13. Ledig, K. W. October 1978. 7-(Substituted)-7H-pyrrolo[3,2,-f]quinazoline- 1,3-diamines. U.S. patent 4,118,561.
14. Ma, N. S., R. N. Rossan, S. T. Kelly, J. S. Harper, M. T. Bedard, and T. C. Jones. 1978. Banding patterns of the chromosomes of two new karyotypes of the owl monkey, Aotus, captured in Panama. J. Med. Primatol. 7:146-155.
15. McCormack, J. J., A. A. Barbara, K. W. Ledig, and B. L. Hillcoat. 1979. Inhibition of dihydrofolate reductases by derivatives of 2,4-diaminopyrrolo- quinazoline. Biochem. Pharmacol. 28:3227-3229.
16. Milhous, W. K., N. F. Weatherly, J. H. Bowdre, and R. E. Desjardins. 1985. In vitro activities of and mechanisms of resistance to antifol antimalarial drugs. Antimicrob. Agents Chemother. 27:525-530.
17. Nosten, F., F. Ter Kuile, T. Chongsuphajaisiddhi, C. Luxemburger, H. K. Webster, M. Edstein, L. Phaipun, and N. J. White. 1982. Mefloquine-resistant Falciparum malaria on the Thai-Burmes border. Lancet 337:1140-1143.
18. Obaldia, N., III. 1991. Detection of Klebsiella pneumoniae antibodies in Aotus l. lemurinus (Panamanian owl monkey) using an enzyme linked immunosorbent assay (ELISA) test. Lab. Anim. 25:133-141.
19. Oduola, A. M., W. K. Milhous, L. A. Salako, O. Walker, and R. E. Desjardins. 1987. Reduced in vitro susceptibility to mefloquine in West African isolates of Plasmodium falciparum. Lancet ii:1304-1305.
20. Oduola, A. M., N. F. Weatherly, J. H. Bowdre, and R. E. Desjardins. 1988. Plasmodium falciparum: cloning by single-erythrocyte micromanipulation and heterogeneity in vitro. Exp. Parasitol. 66:86-95.
21. Peters, W. 1999. The evolution of tafenoquine-antimalarial for a new millennium? J. R. Soc. Med. 92:345-352.
22. Phillips-Howard, P. A., and F. O. ter Kuile. 1995. CNS adverse events associated with antimalarial agents: fact or fiction? Drug Saf. 12:370-383.
23. Rosowsky, A., P. C. Huang, N. Papathanasopoulos, and E. J. Modest. 1974. Quinazolines. 12. 1,3-Diaminobenzo(f)quinazolines containing long-chain alkyl or chloro-substituents on the central ring. Synthesis and biological evaluation as candidate antifolate and antimalarial agents. J. Med. Chem. 17:1217-1222.
24. Schlagenhauf, P. 1999. Mefloquine for malaria chemoprophylaxis 1991-1998: a review. J. Travel Med. 6:122-133.
25. Sweeney, T. 1991. A survey of compounds from the antimalarial drug development program of the U.S. Army Medical Research and Development Command, vol. 1. Walter Reed Army Institute of Research, Silver Spring, Md.
26. Sweeney, T. R. 1991. Thomas R. Sweeney (TRS) malaria compendium, p. 817, Table 100. WRAIR, Silver Spring, Md.
27. Trigg, P. I., and A. V. Kondrachine. 1998. The current global malaria situation, p. 11-22. In I. W. Sherman (ed.), Malaria parasite biology, pathogenesis, and protection. ASM Press, Washington, D.C.
28. Wallace, M. R., T. W. Sharp, B. Smoak, C. Iriye, P. Rozmajzl, S. A. Thornton, R. Batchelor, A. J. Magill, H. O. Lobel, C. F. Longer, and J. P. Burans. 1996. Malaria among United States troops in Somalia. Am. J. Med. 100:49-55.
29. Walsh, D. S., P. Wilairatana, D. B. Tang, D. G. Heppner, Jr., T. G. Brewer, S. Krudsood, U. Silachamroon, W. Phumratanaprapin, D. Siriyanonda, and S. Looareesuwan. 2004. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Clin. Infect. Dis. 39:1095-1103.
30. Walsh, D. S., C. Eamsila, T. Sasiprapha, S. Sangkharomya, P. Khaewsathien, P. Supakalin, D. B. Tang, P. Jarasrumgsichol, C. Cherdchu, M. D. Edstein, K. H. Rieckmann, and T. Brewer. 2004. Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria. J. Infect. Dis. 190:1456-1463.
31. White, N. J. 1998. Drug resistance in malaria. Br. Med. Bull. 54:703-715.
32. World Health Organization. 1997. World malaria situation in 1994. Part I. Population at risk. Wkly. Epidemiol. Rec. 72:269-274.
33. WRAIR. Unpublished data.